What Have We Learned from the Shortening of Treatment for Drug-sensitive TB?

Date:

November 20, 2014 (All Day)

Dr. Richard Chaisson and Dr. Eric Nuermberger talk about what has been learned from recent phase 2 and phase 3 trials of shortening the treatment for drug-sensitive tuberculosis. 

Video/Audio/Slides

Audio-only/Slides

Projects

Assessing the social value of novel regimens...

We are collaborating with investigators from the Berman Bioethics Institute to develop novel techniques for economic evaluation...

Read More

Statins as adjunctive host-directed therapy...

This study will investigate the role of statins in combination with the first-line regimen for TB in the mouse model. In...

Read More

FlexDx-TB: A flexible, user-friendly model of...

We have developed a web-based model that allows decision-makers to input local epidemiological and economic values and receive...

Read More

The role of cell wall lipids in pathogenesis...

This study will use a combination of transcriptional, lipidomic, genetic, and imaging techniques to investigate whether...

Read More

A smoking cessation trial in HIV/AIDS...

A tobacco prevalence survey and smoking cessation trial among HIV infected patients in South Africa.

Read More